Julia J Liu1,2, Thomas Brent Rosson3, Jesse J Xie3,4, Zachary P Harris3,4, Regina G McBride5, Eric Siegel6, Curt Hagedorn3,4. 1. Department of Medicine, Central Arkansas Veterans Healthcare System, Little Rock, AR, USA. jjliu@uams.edu. 2. Division of Gastroenterology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. jjliu@uams.edu. 3. Department of Medicine, Central Arkansas Veterans Healthcare System, Little Rock, AR, USA. 4. Division of Gastroenterology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 5. Department of Nursing, Central Arkansas Veterans Healthcare Systems, Little Rock, AR, USA. 6. Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Abstract
BACKGROUND AND AIMS: IBD patients with inadequately treated disease often relapse and require hospitalizations for further management. The purpose of this practice review was to determine whether personalized IBD care improved patient outcomes as measured by IBD-related hospitalizations. METHODS: A dedicated IBD clinic was created for personalized patient care in a tertiary veterans health care center in 2014. In the first year, the care program consisted of patient-centered medical home (PCMH). In the second year, personalized biologic therapy was incorporated into the program, based on the severity of mucosal barrier dysfunction measured by probe-based confocal laser endomicroscopy (pCLE) analysis of the terminal ileum during colonoscopy. IBD-related hospitalizations during these 2 years were compared to the year before the care program. RESULTS: The IBD-related admissions at baseline, year 1 and 2 of the program were: total number of admissions of 25, 24, 8 (P = 0.03) per year, total number of hospital days of 177, 144, 31 days per year (P < 0.01), median length of stay 7, 4, and 2 days per visit (P = 0.013), respectively. Patients had significant increases in serum hemoglobin (11.5 ± 2.7, 11.9 ± 2.6, 14.0 ± 1.4 g/dl; P = 0.035), albumin (2.7 ± 0.7, 3.0 ± 0.6 g/dl 3.7 ± 0.8 g/dl; P = 0.031) and body mass index (26.6 ± 2.9, 28.1 ± 5.9; 34.0 ± 10.8; P = 0.047). CONCLUSIONS: Personalized IBD care incorporating a PCMH model and tailored biologic therapy based on pCLE findings of mucosal barrier dysfunction significantly reduced IBD-related hospitalizations.
BACKGROUND AND AIMS: IBD patients with inadequately treated disease often relapse and require hospitalizations for further management. The purpose of this practice review was to determine whether personalized IBD care improved patient outcomes as measured by IBD-related hospitalizations. METHODS: A dedicated IBD clinic was created for personalized patient care in a tertiary veterans health care center in 2014. In the first year, the care program consisted of patient-centered medical home (PCMH). In the second year, personalized biologic therapy was incorporated into the program, based on the severity of mucosal barrier dysfunction measured by probe-based confocal laser endomicroscopy (pCLE) analysis of the terminal ileum during colonoscopy. IBD-related hospitalizations during these 2 years were compared to the year before the care program. RESULTS: The IBD-related admissions at baseline, year 1 and 2 of the program were: total number of admissions of 25, 24, 8 (P = 0.03) per year, total number of hospital days of 177, 144, 31 days per year (P < 0.01), median length of stay 7, 4, and 2 days per visit (P = 0.013), respectively. Patients had significant increases in serum hemoglobin (11.5 ± 2.7, 11.9 ± 2.6, 14.0 ± 1.4 g/dl; P = 0.035), albumin (2.7 ± 0.7, 3.0 ± 0.6 g/dl 3.7 ± 0.8 g/dl; P = 0.031) and body mass index (26.6 ± 2.9, 28.1 ± 5.9; 34.0 ± 10.8; P = 0.047). CONCLUSIONS: Personalized IBD care incorporating a PCMH model and tailored biologic therapy based on pCLE findings of mucosal barrier dysfunction significantly reduced IBD-related hospitalizations.
Entities:
Keywords:
Confocal laser endomicroscopy; Hospitalization; Inflammatory bowel disease; Medical home; Personalized medicine
Authors: Anne F Peery; Seth D Crockett; Alfred S Barritt; Evan S Dellon; Swathi Eluri; Lisa M Gangarosa; Elizabeth T Jensen; Jennifer L Lund; Sarina Pasricha; Thomas Runge; Monica Schmidt; Nicholas J Shaheen; Robert S Sandler Journal: Gastroenterology Date: 2015-08-29 Impact factor: 22.682
Authors: Jennifer Jones; Edward V Loftus; Remo Panaccione; Li-Sheng Chen; Sandra Peterson; Joseph McConnell; Linnea Baudhuin; Karen Hanson; Brian G Feagan; Scott W Harmsen; Alan R Zinsmeister; Emelie Helou; William J Sandborn Journal: Clin Gastroenterol Hepatol Date: 2008-09-17 Impact factor: 11.382
Authors: Akbar K Waljee; Rachel Lipson; Wyndy L Wiitala; Yiwei Zhang; Boang Liu; Ji Zhu; Beth Wallace; Shail M Govani; Ryan W Stidham; Rodney Hayward; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2017-12-19 Impact factor: 5.325
Authors: Geoffrey C Nguyen; Thomas A LaVeist; Mary L Harris; Lisa W Datta; Theodore M Bayless; Steven R Brant Journal: Inflamm Bowel Dis Date: 2009-08 Impact factor: 5.325
Authors: C Cellier; T Sahmoud; E Froguel; A Adenis; J Belaiche; J F Bretagne; C Florent; M Bouvry; J Y Mary; R Modigliani Journal: Gut Date: 1994-02 Impact factor: 23.059
Authors: Miguel D Regueiro; Sandra E McAnallen; Julia B Greer; Stephen E Perkins; S Ramalingam; Eva Szigethy Journal: Inflamm Bowel Dis Date: 2016-08 Impact factor: 5.325
Authors: Claudia Ramos-Rivers; Miguel Regueiro; Eric J Vargas; Eva Szigethy; Robert E Schoen; Michael Dunn; Andrew R Watson; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Anwar Dudekula; Ada O Youk; David G Binion Journal: Clin Gastroenterol Hepatol Date: 2013-11-19 Impact factor: 11.382